357 related articles for article (PubMed ID: 23026947)
21. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
22. The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis.
Puri P; Walters GD; Fadia MN; Konia M; Gibson KA; Jiang SH
BMC Nephrol; 2020 Jul; 21(1):265. PubMed ID: 32652953
[TBL] [Abstract][Full Text] [Related]
23. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
24. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.
Nakano M; Karasawa K; Moriyama T; Uchida K; Nitta K
Clin Exp Nephrol; 2019 Jun; 23(6):852-858. PubMed ID: 30854618
[TBL] [Abstract][Full Text] [Related]
26. [Familial membranoproliferative glomerulonephritis].
Bogdanović RM; Dimitrjević JZ; Nikolić VN; Ognjanović MV; Rodić BD; Slavković BV
Srp Arh Celok Lek; 1999; 127(5-6):163-71. PubMed ID: 10500423
[TBL] [Abstract][Full Text] [Related]
27. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
28. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Rudnicki M
Biomed Res Int; 2017; 2017():2180508. PubMed ID: 28573137
[TBL] [Abstract][Full Text] [Related]
29. FHR-5 Serum Levels and
Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
Front Immunol; 2021; 12():720183. PubMed ID: 34566977
[TBL] [Abstract][Full Text] [Related]
30. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J
J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415
[TBL] [Abstract][Full Text] [Related]
31. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
32. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
33. Membranoproliferative glomerulonephritis type III: association of glomerular deposits with circulating nephritic factor-stabilized convertase.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Jul; 32(1):56-63. PubMed ID: 9669425
[TBL] [Abstract][Full Text] [Related]
34. To interpret and analyze the changing patterns of histology and direct immunofluorescence findings in membranoproliferative glomerulonephritis.
Nayak PP; Pradhan P; Pradhan D; Mohapatra N; Raman S; Sahoo P
Indian J Pathol Microbiol; 2024; 67(1):80-85. PubMed ID: 38358193
[TBL] [Abstract][Full Text] [Related]
35. [Membranoproliferative glomerulonephritis and C3 glomerulopathy].
Hohenstein B; Amann K; Menne J
Internist (Berl); 2019 May; 60(5):458-467. PubMed ID: 30859280
[TBL] [Abstract][Full Text] [Related]
36. Serum terminal complement component levels in hypocomplementemic glomerulonephritides.
Clardy CW; Forristal J; Strife CF; West CD
Clin Immunol Immunopathol; 1989 Mar; 50(3):307-20. PubMed ID: 2917423
[TBL] [Abstract][Full Text] [Related]
37. [Clinical approach to primary membranoproliferative glomerulonephritis].
Fakhouri F
Nephrol Ther; 2016 Apr; 12 Suppl 1():S65-9. PubMed ID: 26972096
[TBL] [Abstract][Full Text] [Related]
38. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
39. Membranoproliferative glomerulonephritis in Russian population.
Dobronravov VA; Smirnov AV
Ter Arkh; 2018 Dec; 90(12):39-47. PubMed ID: 30701832
[TBL] [Abstract][Full Text] [Related]
40. Discordant renal histopathologic findings and complement profiles in membranoproliferative glomerulonephritis type III.
Meyers KE; Strife CF; Witzleben C; Kaplan BS
Am J Kidney Dis; 1996 Dec; 28(6):804-10. PubMed ID: 8957031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
